Ponatinib v léčbě pacienta s lymfoblastickým zvratem chronické myeloidní leukemie - význam před- a potransplantačního podání inhibitorů tyrosinkináz
| Title in English | Ponatinib in the treatment of patients with lymphoblastic reversal of chronic myeloid leukemia - the importance of pre- and post-transplant tyrosine kinase inhibitors |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Chapter of a book |
| MU Faculty or unit | |
| Citation | |
| Description | Hematology is one of the traditional components of internal medicine. However, especially the development of hematooncology in recent decades has made hematology a very complex and demanding field with a major societal impact. In addition, hematology and hematooncology are evolving extremely rapidly. This concerns both the changes in the classification of a number of nosological units and, in particular, the rapid introduction of new substances into hematooncological treatment. Advances in diagnosis, and especially targeted and biological treatment, bring new hope to many patients. However, these new therapeutic options are not always fully exploited in practice. |